Bicara Therapeutics Inc (BCAX) Q4 2025 Earnings Call Highlights: Strong Cash Position and ... [Yahoo! Finance]
Bicara Therapeutics Inc. (BCAX)
Company Research
Source: Yahoo! Finance
Cash Equivalents and Marketable Securities: $414.8 million at the start of 2026. Public Offering Proceeds: Raised an additional $161.8 million in net proceeds. Cash Runway Guidance: Maintained into the first half of 2029. Warning! GuruFocus has detected 6 Warning Signs with USAS. Is BCAX fairly valued? Test your thesis with our free DCF calculator. Release Date: March 30, 2026 For the complete transcript of the earnings call, please refer to the full earnings call transcript Positive Points Bicara Therapeutics Inc ( NASDAQ:BCAX ) received Breakthrough Therapy Designation for its lead asset, Fisera, in combination with pembrolizumab for first-line treatment of metastatic or unresectable HPV-negative recurrent head and neck squamous cell carcinoma. The company presented positive Phase 1B clinical data demonstrating consistent overall response rates, validating Fisera's dual mechanism targeting both EGFR and TGF-beta. Bicara Therapeutics Inc ( NASDAQ:BCAX ) successfu
Show less
Read more
Impact Snapshot
Event Time:
BCAX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BCAX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BCAX alerts
High impacting Bicara Therapeutics Inc. news events
Weekly update
A roundup of the hottest topics
BCAX
News
- Bicara: Maintaining 'Buy' Rating On Ficerafusp Alfa Phase 3 Advancement [Seeking Alpha]Seeking Alpha
- Bicara Therapeutics (BCAX) had its price target raised by The Goldman Sachs Group, Inc. from $14.00 to $16.00. They now have a "neutral" rating on the stock.MarketBeat
- Bicara Therapeutics (BCAX) had its price target raised by Wells Fargo & Company from $11.00 to $16.00. They now have an "equal weight" rating on the stock.MarketBeat
- Bicara Therapeutics (BCAX) had its "outperform" rating reaffirmed by Wedbush. They now have a $30.00 price target on the stock.MarketBeat
- Bicara Therapeutics (BCAX) had its "market outperform" rating reaffirmed by Citizens Jmp. They now have a $31.00 price target on the stock.MarketBeat
BCAX
Earnings
- 3/30/26 - Beat
BCAX
Sec Filings
- 3/31/26 - Form S-8
- 3/30/26 - Form 10-K
- 3/30/26 - Form 8-K
- BCAX's page on the SEC website